nach oben

Indian Journal of Hematology and Blood Transfusion

Erschienen in:

30.09.2017 | Original Article

Bufalin Enhances the Cytotoxity of Human Multiple Myeloma Cells H929 to AKT Inhibitor MK2206: The Role of Protein AKT Phosphorylation

verfasst von: He Huang, Xiao-ji Lin, Ying Lin, Ron-xin Yao, Mu-qing He

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

This study was purposed to investigate bufalin combined with AKT inhibitor MK2206 on growth inhibition and apoptosis of multiple myeloma cell line H929. CCK-8 assay and Annexin/PI staining were used to access the effects of bufalin and MK2206 in single or in combination, on inhibition of proliferation and induction of apoptosis in H929 cells. The apoptotic cells markedly increased after treated with nM bufalin and μM MK2206, including caspase3 and PARP1 proteins activated. The difference was statistically significant (P < 0.05) when compared with these drugs in single use. The apoptosis associated proteins and AKT/p-AKT proteins were determined by Western blots. We confirmed that AKT performed contradictory results in H929 with the two agents, and concluded p-AKT was vital in the synergy. The underlying mechanisms warrant further investigation.

Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346CrossRefPubMed

Hsu J, Shi Y, Krajewski S et al (2001) The AKT kinase is activated in multiple myeloma tumor cells. Blood 98(9):2853–2855CrossRefPubMed

Keane NA, Glavey SV, Krawczyk J et al (2014) AKT as a therapeutic target in multiple myeloma. Expert Opin Ther Targets 18(8):897–915CrossRefPubMed

Toker A, Yoeli-Lerner M (2006) Akt signaling and cancer: surviving but not moving on. Cancer Res 66(8):3963–3966CrossRefPubMed

Song G, Ouyang G, Bao S (2005) The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9(1):59–71CrossRefPubMed

Hirai H, Sootome H, Nakatsuru Y et al (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9(7):1956–1967CrossRefPubMed

Ramakrishnan V, Kimlinger T, Haug J et al (2012) Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. PLoS ONE 7(11):e50005CrossRefPubMedPubMedCentral

Huang H, Cao Y, Wei W et al (2013) Targeting poly (ADP-ribose) polymerase partially contributes to bufalin-induced cell death in multiple myeloma cells. PLoS ONE 8(6):e66130CrossRefPubMedPubMedCentral

Zhang LS, Nakaya K, Yoshida T et al (1991) Bufalin as a potent inducer of differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 178(2):686–693CrossRefPubMed

10.

Zhang L, Nakaya K, Yoshida T et al (1992) Induction by bufalin of differentiation of human leukemia cells HL60, U937, and ML1 toward macrophage/monocyte-like cells and its potent synergistic effect on the differentiation of human leukemia cells in combination with other inducers. Cancer Res 52(17):4634–4641PubMed

11.

Chen A, Yu J, Zhang L, Sun Y et al (2009) Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 Cells. Biotechnol Lett 31(4):487–494CrossRefPubMed

12.

Yeh JY, Huang WJ, Kan SF et al (2003) Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 54(2):112–124CrossRefPubMed

13.

Takai N, Ueda T, Nishida M et al (2008) Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med 21(5):637–643PubMed

14.

Li D, Qu X, Hou K et al (2009) PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anticancer Drugs 20(20):59–64CrossRefPubMed

15.

Meng Z, Yang P, Shen Y et al (2009) Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer 115(22):5309–5318CrossRefPubMedPubMedCentral

16.

Qi F, Li A, Zhao L et al (2010) Cinobufacini, an aqueous extract from Bufo bufo gargarizans Cantor, induces apoptosis through a mitochondria-mediated pathway in human hepatocellular carcinoma cells. J Ethnopharmacol 128(3):654–661CrossRefPubMed

17.

Takai N, Kira N, Ishii T et al (2012) Bufalin, a traditional oriental medicine, induces apoptosis in human cancer cells. Asian Pac J Cancer Prev 13(1):399–402CrossRefPubMed

18.

Arnaud-Batista FJ, Costa GT, Oliveira IM et al (2012) Natriuretic effect of bufalin in isolated rat kidneys involves activation of the Na⁺-K⁺-ATPase-Src kinase pathway. Am J Physiol Renal Physiol 302(8):F959–F966CrossRefPubMed

19.

Zhao Y, Pu JX, Huang SX et al (2009) ent-Kaurane diterpenoids from Isodon pharicus. J Nat Prod 72(6):988–993CrossRefPubMed

20.

Yin PH, Liu X, Qiu YY et al (2012) Anti-tumor activity and apoptosis-regulation mechanisms of bufalin in various cancers: new hope for cancer patients. Asian Pac J Cancer Prev 13(11):5339–5343CrossRefPubMed

21.

Xu N, Lao Y, Zhang Y et al (2012) Akt: a double-edged sword in cell proliferation and genome stability. J Oncol 2012:951724CrossRefPubMedPubMedCentral

22.

Demel HR, Feuerecker B, Piontek G et al (2015) Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells. Am J Cancer Res 5(5):1649–1664PubMedPubMedCentral

Titel: Bufalin Enhances the Cytotoxity of Human Multiple Myeloma Cells H929 to AKT Inhibitor MK2206: The Role of Protein AKT Phosphorylation
verfasst von: He Huang
Xiao-ji Lin
Ying Lin
Ron-xin Yao
Mu-qing He
Publikationsdatum: 30.09.2017
Verlag: Springer India
Erschienen in: Indian Journal of Hematology and Blood Transfusion / Ausgabe 2/2018
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-017-0883-z

Springer Medizin

Bufalin Enhances the Cytotoxity of Human Multiple Myeloma Cells H929 to AKT Inhibitor MK2206: The Role of Protein AKT Phosphorylation

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

“Everything that Glows on PET is not Lymphoma”: An Unheralded Intruder in a Case of Diffuse Large B Cell Lymphoma

Myeloperoxidase Deficient Acute Promyelocytic Leukemia: Report of Two Cases

Autologous Stem Cell Transplantation for Multiple Myeloma: Single Centre Experience from North India

Fast Track Anaemia Clinic (FTAC) and Intravenous Iron Administration: Its Relevance and Application Today in India

Anxiety, Depression and Distress Among Children Undergoing Haematopoietic Stem Cell Transplantation and Its Correlation with Age and Socio-economic Status: A Single Centre Experience from India

Correction to: The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie